公开(公告)号：US20230036453A1

公开(公告)日：2023-02-02

申请号：US17745204

申请日：2022-05-16

Applicant: Beth Israel Deaconess Medical Center, Inc.

Inventor： David ALSOP ,  Aaron GRANT

IPC: G01R33/28 ,  A61K49/08 ,  A61K49/10 ,  G01R33/30 ,  G01R33/56

Abstract: Systems and methods are provided for producing hyperpolarized materials for use during a magnetic resonance imaging (MRI) or nuclear magnetic resonance (NMR) process. The system and methods include the use of microfluidic and/or microreactor methods in one or more of the stages of parahydrogen production, enriched substrate production, and spin order transfer from the parahydrogen to a substrate.

公开(公告)号：US20230001024A1

公开(公告)日：2023-01-05

申请号：US17774529

申请日：2020-11-06

Applicant: North Carolina State University

Inventor： Jonathan S. Lindsey ,  Zhiyuan Wu ,  Hikaru Fujita ,  Daisuke Sato

IPC: A61K49/10 ,  A61K31/7135 ,  A61K47/54 ,  A61K49/16 ,  C12N9/24

Abstract: Compounds of Formula IA, IB, II, III, IV, and/or V are described herein along with their methods of use. A compound of the present invention may cross-link under physiological conditions and/or in vivo.

公开(公告)号：US11534506B2

公开(公告)日：2022-12-27

申请号：US15555775

申请日：2016-03-07

Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

Inventor： Aditya Bansal ,  Timothy R. DeGrado ,  Mukesh K. Pandey

IPC: A61K51/04 ,  A61K51/12 ,  A61K49/10 ,  A61K49/18

Abstract: Methods of ex vivo labeling of a biological material for in vivo imaging, methods of labeling a biological material in vivo, methods for preparing a labeling agent, and methods for in vivo imaging of a subject using a biological material labeled with a labeling agent are disclosed. In one non-limiting example, the biological material is selected from cells and the labeling agent is a 89Zr-Desferrioxamine-NCS labeling agent.

公开(公告)号：US11433148B2

公开(公告)日：2022-09-06

申请号：US15971980

申请日：2018-05-04

Applicant: Centre for Probe Development and Commercialization

Inventor： Eric Steven Burak ,  John Richard Forbes ,  Matthew David Burr Moran ,  Ryan Wayne Simms ,  John Fitzmaurice Valliant ,  Alla Darwish

IPC: A61K51/04 ,  A61P35/00 ,  A61K51/10 ,  A61K49/10 ,  C07K16/28 ,  C07K16/26

Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.

公开(公告)号：US20220249707A1

公开(公告)日：2022-08-11

申请号：US17612968

申请日：2020-05-19

Applicant: NIRvana Sciences Inc.

Inventor： Christopher J. MacNevin ,  James Bruce Pitner ,  Chih-Yuan Chen

IPC: A61K49/10 ,  C09K11/06 ,  C09B47/30 ,  C07F3/06 ,  C07D487/22

Abstract: Provided are chlorin derivatives with narrow band emission. In some embodiments, the bacteriochlorin derivatives are PEGylated. In some embodiments, the chlorin derivatives have high water solubility (e.g., 10 mg/mL or more). In some embodiments, the chlorin derivatives are PEGylated and have high water solubility. The chlorin derivatives can include bioconjugatable groups for forming conjugates, for example, with antibodies and nanoparticles. The chlorin derivatives and their conjugates can be used in imaging and therapeutic applications. Methods of synthesizing the chlorin derivatives are also provided.

公开(公告)号：US20220218849A1

公开(公告)日：2022-07-14

申请号：US17609979

申请日：2020-05-27

Applicant: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V.V.I.

Inventor： Miloslav POLASEK ,  Jan KRETSCHMER

IPC: A61K49/10 ,  C07F5/00 ,  C07K5/078 ,  C07D403/04 ,  C07D403/14 ,  A61K49/14

Abstract: Cyclen based compounds of general formula (I) are disclosed. X is nitrogen and Y, Z are —CH—, or X, Z are —CH— and Y is nitrogen, or X, Y are —CH— and Z is nitrogen. R1 is independently selected from H; COOH; benzyloxycarbonyl; fluorenylmethyloxycarbonyl; tert-butoxycarbonyl; methylcarbonyl; trifluoromethylcarbonyl; benzyl; triphenylmethyl; tosyl; mesyl; benzyloxymethyl; phenylsulfonyl; ethoxycarbonyl; 2,2,2-trichloroethyloxycarbonyl; methoxycarbonyl; methoxymethyloxycarbonyl; R2 is selected from H; methylcarbonyl; tert-butyldimethylsilyl; (C1-C4)alkyl; R3 is independently selected from H; (C1-C6)alkyl.

公开(公告)号：US20220211880A1

公开(公告)日：2022-07-07

申请号：US17520133

申请日：2021-11-05

Applicant: Massachusetts Institute of Technology

Inventor： Alan Pradip Jasanoff ,  Jacob Simon

IPC: A61K49/18 ,  A61K47/24 ,  A61K47/28 ,  A61K49/10

Abstract: The present disclosure provides imaging and contrast agents, and methods of using the agents. According to some embodiments of the disclosure, agents and methods for magnetic resonance imaging and related technologies are provided.

公开(公告)号：US11366186B2

公开(公告)日：2022-06-21

申请号：US16323596

申请日：2017-08-09

Applicant: Beth Israel Deaconess Medical Center, Inc.

Inventor： David Alsop ,  Aaron Grant

IPC: G01R33/28 ,  A61K49/08 ,  A61K49/10 ,  G01R33/30 ,  G01R33/56

Abstract: Systems and methods are provided for producing hyperpolarized materials for use during a magnetic resonance imaging (MRI) or nuclear magnetic resonance (NMR) process. The system and methods include the use of microfluidic and/or microreactor methods in one or more of the stages of parahydrogen production, enriched substrate production, and spin order transfer from the parahydrogen to a substrate.

公开(公告)号：US11330999B2

公开(公告)日：2022-05-17

申请号：US16646549

申请日：2018-09-10

Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER

Inventor： Andrew Cho ,  Roozbeh Eskandari ,  Valentina Di Gialleonardo ,  Kayvan R. Keshari

IPC: A61B5/055 ,  C07B59/00 ,  C07C237/06 ,  C07C279/14 ,  C07D473/06 ,  A61K49/10

Abstract: The present technology provides 13C- and 15N-labeled probes for imaging one or more mammalian cells using magnetic resonance. Thus, 13C- and 15N-labeled arginine (compound of formula I), xanthine (compounds of formula II and formula III), urea (compounds of formula IV), and glutamine (compounds of formula V), stereoisomers, tautomers, and pharmaceutically acceptable salts thereof are provided. Further methods of making the labelled probes and methods of using the probes to detect arginase, xanthine oxidase, and glutaminase metabolites and activity are provided.

公开(公告)号：US20220080058A1

公开(公告)日：2022-03-17

申请号：US17534232

申请日：2021-11-23

Applicant: INVENTURE, LLC

Inventor： Richard Deslauriers ,  Michael Milbocker

IPC: A61K49/10 ,  A61K49/18

Abstract: Gadolinium based contrast agents (GCA) incorporating linear ligand chelation are fundamentally different from GCAs incorporating macrocyclic ligands. The macrocyclic\GCAs are synthesized by pathways characterized by the formation of a sequence of metastable complexes before obtaining the final stable complex. The synthesis of linear GCAs do not form metastable complexes. Commercial macrocyclic GCAs contain unstable metastable complexes. These metastable species are not regulated and quickly release free Gd3+ ions upon administration into the body. Gadolinium based contrast agents with near zero metastable species content and methods of synthesizing the same are disclosed. Gadolinium based contrast agents with long dissociation time in the body, and low free Gd3+ ion formation are obtained using a synthesis method which departs in novel ways from the traditional free Gd3+-based synthesis methods.